Cell-based and xenograft assays using NTRK1 inhibitors in NTRK1 transformed cells led to inhibition of cellular proliferation and tumor shrinkage, respectively, indicated NTRK1 rearrangement are indeed a driver mutation in NSCLC (4). This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.